- Home
- BKYI vs KPRX Comparison
BKYI vs KPRX Comparison
Compare BKYI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKYI | KPRX |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 7.5M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | BKYI | KPRX |
|---|---|---|
| Price | $0.58 | $1.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 278.2K | 35.1K |
| Earning Date | 11-14-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,316,050.00 | N/A |
| Revenue This Year | $7.45 | N/A |
| Revenue Next Year | $23.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $1.77 |
| 52 Week High | $3.68 | $4.18 |
Technical Indicators
Market Signals| Indicator | BKYI | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 41.02 |
| Support Level | $0.53 | $1.89 |
| Resistance Level | $0.63 | $2.02 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 21.48 | 17.65 |
Price Performance
Historical ComparisonAbout BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.